向特定对象发行A股股票

Search documents
北方国际: 九届六次监事会决议公告
Zheng Quan Zhi Xing· 2025-05-29 12:08
二、会议审议通过《关于公司 2024 年度向特定对象发行 A 股股票预案(修 订稿)的议案》。 股票简称:北方国际 股票代码:000065 公告编号:2025-057 北方国际合作股份有限公司 本公司及监事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、 误导性陈述或者重大遗漏。 北方国际合作股份有限公司(以下简称"公司"或"北方国际")九届六次 监事会会议于 2025 年 5 月 29 日以通讯会议表决的形式召开。由于相关议案需要 监事会尽快作出决议,为维护公司利益,会议通知于 2025 年 5 月 28 日以邮件方 式发送至全体监事,全体监事一致同意豁免本次会议通知时限。本次会议应参与 审议表决的监事 3 名,实际参与审议表决的监事 3 名,会议由监事会召集人李正 安主持。会议召开程序符合《中华人民共和国公司法》和《公司章程》的有关规 定,会议合法有效。经全体参会监事审议: 一、会议审议通过了《关于调整公司向特定对象发行 A 股股票方案的议案》。 表决结果:同意 3 票,反对 0 票,弃权 0 票。 公司根据《中华人民共和国公司法》《中华人民共和国证券法》及《上市公 司证券发行注册管理办法》等相关 ...
天音控股: 关于2023年度向特定对象发行A股股票摊薄即期回报、填补措施及相关主体承诺(四次修订稿)的公告
Zheng Quan Zhi Xing· 2025-05-28 08:17
Core Viewpoint - Tianyin Communication Holdings Co., Ltd. plans to issue A-shares to specific investors, which may dilute immediate returns for existing shareholders, but the company has committed to measures to compensate for this dilution [1][4][6]. Group 1: Impact Analysis of Share Issuance - The total amount to be raised from the issuance is 1,708 million yuan [1]. - The analysis of the impact on key financial indicators is based on three scenarios: net profit remaining flat, increasing by 10%, and decreasing by 10% compared to 2024 [1][2][3]. - In the scenario where net profit remains flat, the diluted earnings per share (EPS) would be 0.03 yuan, while the basic EPS would also be 0.03 yuan [2][3]. - In the scenario of a 10% increase in net profit, the diluted EPS would be 0.03 yuan, and the basic EPS would be 0.03 yuan [3]. - In the scenario of a 10% decrease in net profit, the diluted EPS would drop to 0.02 yuan, and the basic EPS would also be 0.02 yuan [3]. Group 2: Necessity and Reasonableness of the Issuance - The issuance is deemed necessary to support projects closely related to the company's main business, including marketing network construction and digital platform development [4][6]. - The projects are expected to enhance the company's market competitiveness and align with its strategic development goals [6][7]. Group 3: Measures to Mitigate Dilution Risk - The company plans to strengthen the management of raised funds to ensure they are used effectively and in compliance with regulations [5][7]. - It aims to ensure the timely progress of investment projects to maximize the efficiency of fund usage and achieve expected benefits quickly [7][8]. - The company will adhere to a strict cash dividend policy to enhance investor return mechanisms [8]. Group 4: Commitments from Management - The company's directors and senior management have committed to fulfilling their responsibilities diligently and protecting the interests of all shareholders [6][9]. - The controlling shareholder has also pledged not to interfere with the company's management and to protect its interests [6][9].
天音控股: 2025年第二次独立董事专门会议的审核意见
Zheng Quan Zhi Xing· 2025-05-28 08:17
天音通信控股股份有限公司 经审议,我们认为公司编制的《天音通信控股股份有限公司 2023 年度向特 定对象发行 A 股股票的论证分析报告(四次修订稿)》符合《公司法》 《证券法》 《上市公司证券发行注册管理办法》等法律、法规和规范性文件的规定,不存在 损害公司及全体股东特别是中小股东利益的行为。我们一致同意该议案,并同意 将该议案提交公司第九届董事会第三十八次会议审议。 天音通信控股股份有限公司于 2025 年 5 月 27 日召开 2025 年第二次独立董 事专门会议,根据《中华人民共和国公司法》《上市公司独立董事管理办法》等 法律法规以及《公司章程》的有关规定,作为天音通信控股股份有限公司(以下 简称"公司")独立董事,我们本着对公司、全体股东及投资者负责的态度,基 于独立判断的立场,对公司第九届董事会第三十八次会议相关事项进行了审议并 发表以下意见: 一、《关于调整公司 2023 年度向特定对象发行 A 股股票方案的议案》的审 核意见 经审议,我们认为本次对公司 2023 年度向特定对象发行 A 股股票方案中的 "募集资金规模和用途"的相关内容的调整符合《公司法》《证券法》《上市公 司证券发行注册管理办 ...
兴齐眼药: 第五届董事会第九次会议决议公告
Zheng Quan Zhi Xing· 2025-05-27 11:07
证券代码:300573 证券简称:兴齐眼药 公告编号:2025-021 沈阳兴齐眼药股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 过电子邮件等形式送达至各位董事,董事会会议通知中包括会议的相关资料,同 时列明了会议的召开时间、地点、内容和方式。 的方式召开。 本次董事会。 二、董事会会议审议情况 会议审议并通过了如下议案: (一)审议通过《关于公司符合向特定对象发行 A 股股票条件的议案》 根据《中华人民共和国公司法》 《中华人民共和国证券法》 《上市公司证券发 行注册管理办法》等有关法律法规的规定,对照上市公司向特定对象发行股票的 条件,董事会对公司的实际情况及相关事项进行认真的自查论证后,认为公司符 合向特定对象发行 A 股股票的资格和条件,同意公司申请本次向特定对象发行人 民币普通股(A 股)股票(以下简称"本次发行")。 表决结果:9 票赞成,0 票反对,0 票弃权。 本议案已经公司董事会审计委员会、独立董事专门会议审议通过。尚需提交 股东大会审议。 律法规和《公司章程》的有关规定。 (二)审议通过《关于公司 2 ...
兴齐眼药: 第五届董事会独立董事专门会议2025年第二次会议决议
Zheng Quan Zhi Xing· 2025-05-27 11:07
一、审议通过《关于公司符合向特定对象发行A股股票条件的议案》 经审议,独立董事认为,公司符合《中华人民共和国公司法》《中华人民共和国 证券法》《上市公司证券发行注册管理办法》等法律法规、规范性文件关于向特定对 象发行A股股票的有关规定,具备向特定对象发行A股股票的条件。 沈阳兴齐眼药股份有限公司 第五届董事会独立董事专门会议 2025 年第二次会议决议 沈阳兴齐眼药股份有限公司(以下简称"公司")第五届董事会独立董事专门 会议 2025 年第二次会议通知于会议召开前 3 日以电子邮件的形式发出,会议于 2025 年5月27 日在公司会议室以现场与通讯会议相结合的方式召开。公司独立董事共 3 人, 出席本次会议的独立董事共 3 人,会议由独立董事徐先梅女士召集并主持。本次会 议的召开符合《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规 则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 及《沈阳兴齐眼药股份有限公司章程》(以下简称"《公司章程》")等有关规定, 会议形成的决议合法、有效。与会独立董事经认真讨论,形成如下决议: 独立董事一致同意该议案,并同意将本议案提交公司 ...
广生堂: 国浩律师(上海)事务所关于福建广生堂药业股份有限公司2025年度向特定对象发行A股股票之法律意见书
Zheng Quan Zhi Xing· 2025-05-23 13:14
Core Viewpoint - Fujian Guangshentang Pharmaceutical Co., Ltd. is preparing to issue A-shares to specific investors in 2025, with the aim of raising funds for various projects, including innovative drug research and traditional Chinese medicine industrialization. Group 1: Issuance Details - The company plans to issue no more than 47,780,100 A-shares, which will not exceed 30% of the total share capital before the issuance [12][14] - The total amount to be raised is not more than 976.87 million yuan, with funds allocated to innovative drug research, traditional Chinese medicine industrialization, and working capital [15] - The issuance will be conducted through a specific object issuance method, targeting up to 35 specific investors, including qualified institutional investors and natural persons [12][15] Group 2: Legal Compliance and Approval - The board of directors and the shareholders' meeting have approved the issuance plan, ensuring compliance with the Company Law and the company's articles of association [11][16] - The issuance is subject to approval from the Shenzhen Stock Exchange and registration by the China Securities Regulatory Commission [16][17] - The company has conducted thorough legal due diligence to ensure compliance with relevant laws and regulations [6][24] Group 3: Company Structure and Independence - Fujian Guangshentang Pharmaceutical is a legally established joint-stock company with independent operations, assets, and financial management [24][26] - The company has no business relationships with its controlling shareholders that would compromise its independence [25][26] - The controlling shareholder, Aohua Group, holds 17% of the shares, while the actual controllers have a combined voting power of 40.89% [27][28] Group 4: Financial and Operational Integrity - The company has maintained a clean legal record, with no significant violations or administrative penalties in the past three years [20][21] - The financial statements have been audited and comply with accounting standards, ensuring transparency and reliability [20][21] - The company has established a robust governance structure, with independent management and operational capabilities [25][26]
云中马: 浙江云中马股份有限公司关于向特定对象发行A股股票摊薄即期回报、采取填补措施及相关主体承诺的公告
Zheng Quan Zhi Xing· 2025-05-23 10:25
Core Viewpoint - The company plans to issue A-shares to specific investors, which will dilute immediate returns but includes measures to compensate for this dilution [1][4][8]. Financial Impact - The issuance will increase the total share capital from 137,514,200 shares to 178,768,460 shares [2][3]. - Three scenarios for net profit after non-recurring gains for 2025 are considered: a 10% increase, no change, and a 10% decrease compared to 2024 [1][2]. Issuance Necessity and Reasonableness - The total amount raised from the issuance will not exceed 640 million yuan, which will be invested in a project to produce 135,000 tons of DTY yarn and 120,000 tons of high-performance leather base fabric [4][5]. - The project aims to enhance production capacity and improve product quality, thereby increasing market share and competitiveness [6][7]. Project Relationship with Existing Business - The investment project is aligned with the company's current operations and aims to upgrade production capacity and extend the industrial chain [6][7]. - The project will allow the company to control product quality more effectively by shifting from external procurement to internal production of key raw materials [6][7]. Human Resources, Technology, and Market Readiness - The company has a strong team of experienced personnel in DTY yarn and fabric production, ensuring effective project implementation [6][7]. - The company possesses significant technological capabilities with numerous patents, which will support the successful execution of the project [7]. - The project is expected to have a positive market reception, with a substantial portion of production being absorbed internally, enhancing the company's market influence [7]. Measures to Mitigate Dilution of Immediate Returns - The company will strengthen the supervision of raised funds to ensure they are used effectively and legally [9]. - There will be an emphasis on accelerating project construction to enhance profitability and shareholder returns [9][10]. - The company will maintain and optimize its profit distribution system to reinforce investor return mechanisms [10]. Commitments to Ensure Implementation of Compensation Measures - The controlling shareholder and management have made commitments to ensure the effectiveness of measures to compensate for the dilution of immediate returns [11]. - These commitments include adherence to regulatory requirements and accountability for any losses incurred due to non-compliance [11].
云中马: 浙江云中马股份有限公司第三届监事会第十三次会议决议公告
Zheng Quan Zhi Xing· 2025-05-23 10:10
证券代码:603130 证券简称:云中马 公告编号:2025-019 浙江云中马股份有限公司 第三届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 浙江云中马股份有限公司(以下简称"公司")第三届监事会第十三次会议 于 2025 年 5 月 22 日以现场结合通讯的方式在公司会议室召开。会议通知经全体 监事同意,豁免通知时限的要求,于当日以电话、口头的方式发出。会议应出席 监事 3 人,实际出席监事 3 人(其中:单晓秋以通讯方式出席)。会议由监事会 主席单晓秋女士召集并主持,会议的召集、召开和表决程序符合《中华人民共和 国公司法》等相关法律法规、部门规章、规范性文件及《浙江云中马股份有限公 司章程》 《公司章程》")的规定。全体监事经过审议,以记名投票方 式通过了如下决议: 二、监事会会议审议情况 本次会议审议并通过了以下事项: (以下简称" (一)审议通过《关于公司符合向特定对象发行股票条件的议案》 根据《中华人民共和国公司法》 《中华人民共和国证券法》 《上市公司证券发 ...
盛美上海: 关于向特定对象发行A股股票摊薄即期回报与公司采取填补措施及相关主体承诺(二次修订稿)的公告
Zheng Quan Zhi Xing· 2025-05-21 12:09
Core Viewpoint - The company plans to issue A-shares to specific investors, aiming to raise up to RMB 4.482 billion for R&D, process testing platform construction, high-end semiconductor equipment iteration, and working capital supplementation [1][2]. Financial Impact - The issuance is expected to dilute immediate returns for existing shareholders, with potential impacts on key financial metrics such as earnings per share [3][4]. - The total share capital post-issuance could reach approximately 48.54 million shares, depending on various profit scenarios for 2025 [4][5]. Necessity and Reasonableness of the Issuance - The fundraising is aligned with the company's long-term development strategy and aims to enhance its competitive position in the semiconductor equipment industry [7][8]. - The projects funded by this issuance are closely related to the company's existing business, focusing on R&D and technological advancements [6][9]. Company’s Technological and Market Position - The company has established a strong presence in the semiconductor equipment sector, recognized for its advanced technologies and a comprehensive product line [11][10]. - The company has accumulated significant intellectual property, with 470 patents, enhancing its competitive edge [10]. Measures to Mitigate Dilution of Immediate Returns - The company plans to enhance its overall strength and expand its business scale post-issuance, improving risk resistance and market value [12]. - Internal management will be strengthened to reduce operational costs and improve efficiency [12]. - The company will accelerate the implementation of fundraising projects to achieve expected returns quickly [12][13]. Commitments from Management and Shareholders - The board and senior management have committed to fulfilling the measures to mitigate the dilution of immediate returns, ensuring the protection of shareholder interests [14].
盛美上海: 第二届监事会第十九次会议决议公告
Zheng Quan Zhi Xing· 2025-05-21 12:00
Group 1 - The company held its 19th meeting of the second supervisory board, which was legally valid and attended by all three supervisors [1] - The supervisory board approved several proposals related to the issuance of A-shares to specific targets for the year 2024, with unanimous support from all supervisors [1][2] - The approved proposals include the conditions for issuing A-shares, adjustments to the issuance plan, and feasibility analyses regarding the use of raised funds, all receiving 100% approval [2] Group 2 - The company confirmed that the raised funds will be directed towards technology innovation, as outlined in the approved proposals [2]